DexCom's fundamentals have strengthened materially, with gross margin rising from 56.9% in 2025Q1 to 64.3% in 2026Q3 and operating margin reaching 24.3% in the latest two quarters, suggesting manufacturing scale is flowing through to profitability.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth moved from 2.0% in 2024Q3 to 15.0% in 2026Q1 before easing to 11.2% in 2026Q3, while gross margin expanded roughly 740 basis points to 64.3% and operating margin reached 24.3%, though net income in 2025Q3 ($283.8M) exceeded operating income ($242.5M), warranting scrutiny of non-operating contributions.
Dexcom has set the standard in glucose biosensing for 25 years, with best-in-class technologies and continuous product innovation.
The company is expanding its market reach into Type 2 diabetes, driving user growth and broadening its customer base.
Dexcom has significant institutional backing, with top holder Vanguard Group owning 11% of the company, indicating strong investor confidence.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $0.73+8.1% vs $0.68 | $1.3B+1.2% vs $1.3B |
Q3 2026 Jul 30, 2026 | $0.70+14.6% vs $0.61 | $1.3B+1.4% vs $1.3B |
Q2 2026 Apr 30, 2026 | $0.56+20.3% vs $0.47 | $1.2B+1.5% vs $1.2B |
Q1 2026 Feb 12, 2026 | $0.68+4.6% vs $0.65 | $1.3B+0.9% vs $1.2B |
DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
DexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported higher profitability.
DexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.
Benchmark DXCM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for DexCom, Inc. (DXCM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $79.41 | $30.64B | 30.73 | 15.6% | 19.41% | 36.5% | — | |
| $109.93 | $191.48B | 40.64 | 5.67% | 9.75% | 9% | 2.14% | |
| $146.51 | $10.15B | 23.74 | 30.73% | 13.45% | 29.48% | — | |
| $16.91 | $1.16B | -23.92 | 7.93% | -4.58% | -35.61% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — |
DexCom, Inc. (DXCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
DexCom, Inc. (DXCM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Jul 30, 2026·SEC
May 28, 2026·SEC
Get notified when DXCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DexCom, Inc. (DXCM) stock FAQ — growth, dividends, profitability & financials explained
DexCom, Inc. (DXCM) reported $5.10B in revenue over the trailing twelve months. Revenue was $4.66B in fiscal year 2025.
DexCom, Inc. (DXCM) grew revenue by 13.0% over the trailing twelve months, compared with the twelve months before.
Yes. DexCom, Inc. (DXCM) earned $991.0M in net income over the trailing twelve months (a 19.4% net margin).
DexCom, Inc. (DXCM) had a return on equity (ROE) of 36.5% over the trailing twelve months. That is well above the market's typical 10-15%.
DexCom, Inc. (DXCM) generated $1.10B in free cash flow over the trailing twelve months.
